Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury

Abstract Background The benzodiazepine midazolam is a γ-aminobutyric acid (GABA)-A receptor agonist frequently used for sedation or stress control in patients suffering from traumatic brain injury (TBI). However, experimental studies on benzodiazepines have reported divergent results, raising concer...

Full description

Bibliographic Details
Main Authors: Anne Sebastiani, Simone Bender, Michael K. E. Schäfer, Serge C. Thal
Format: Article
Language:English
Published: BMC 2022-03-01
Series:BMC Anesthesiology
Subjects:
Online Access:https://doi.org/10.1186/s12871-022-01592-x
_version_ 1818917996798672896
author Anne Sebastiani
Simone Bender
Michael K. E. Schäfer
Serge C. Thal
author_facet Anne Sebastiani
Simone Bender
Michael K. E. Schäfer
Serge C. Thal
author_sort Anne Sebastiani
collection DOAJ
description Abstract Background The benzodiazepine midazolam is a γ-aminobutyric acid (GABA)-A receptor agonist frequently used for sedation or stress control in patients suffering from traumatic brain injury (TBI). However, experimental studies on benzodiazepines have reported divergent results, raising concerns about its widespread use in patients. Some studies indicate that benzodiazepine-mediated potentiation of GABAergic neurotransmission is detrimental in brain-injured animals. However, other experimental investigations demonstrate neuroprotective effects, especially in pretreatment paradigms. This study investigated whether single-bolus midazolam administration influences secondary brain damage post-TBI. Methods Two different midazolam dosages (0.5 and 5 mg/kg BW), a combination of midazolam and its competitive antagonist flumazenil, or vehicle solution (NaCl 0.9%) was injected intravenously to mice 24 h after experimental TBI induced by controlled cortical impact. Mice were evaluated for neurological and motor deficits using a 15-point neuroscore and the rotarod test. Histopathological brain damage and mRNA expression of inflammatory marker genes were analyzed using quantitative polymerase chain reaction three days after insult. Results Histological brain damage was not affected by posttraumatic midazolam administration. Midazolam impaired functional recovery, and this effect could not be counteracted by administering the midazolam antagonist flumazenil. An increase in IL-1β mRNA levels due to postinjury application of midazolam was reversible by flumazenil administration. However, other inflammatory parameters were not affected. Conclusions This study merely reports minor effects of a postinjury midazolam application. Further studies focusing on a time-dependent analysis of posttraumatic benzodiazepine administration are required.
first_indexed 2024-12-20T00:42:57Z
format Article
id doaj.art-b92422003b67403ca2354345eba2c25c
institution Directory Open Access Journal
issn 1471-2253
language English
last_indexed 2024-12-20T00:42:57Z
publishDate 2022-03-01
publisher BMC
record_format Article
series BMC Anesthesiology
spelling doaj.art-b92422003b67403ca2354345eba2c25c2022-12-21T19:59:30ZengBMCBMC Anesthesiology1471-22532022-03-0122111010.1186/s12871-022-01592-xPosttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injuryAnne Sebastiani0Simone Bender1Michael K. E. Schäfer2Serge C. Thal3Department of Anesthesiology, HELIOS University Hospital Wuppertal, University of Witten/HerdeckeDepartment of Anesthesiology, University Medical Center of the Johannes Gutenberg UniversityDepartment of Anesthesiology, University Medical Center of the Johannes Gutenberg UniversityDepartment of Anesthesiology, HELIOS University Hospital Wuppertal, University of Witten/HerdeckeAbstract Background The benzodiazepine midazolam is a γ-aminobutyric acid (GABA)-A receptor agonist frequently used for sedation or stress control in patients suffering from traumatic brain injury (TBI). However, experimental studies on benzodiazepines have reported divergent results, raising concerns about its widespread use in patients. Some studies indicate that benzodiazepine-mediated potentiation of GABAergic neurotransmission is detrimental in brain-injured animals. However, other experimental investigations demonstrate neuroprotective effects, especially in pretreatment paradigms. This study investigated whether single-bolus midazolam administration influences secondary brain damage post-TBI. Methods Two different midazolam dosages (0.5 and 5 mg/kg BW), a combination of midazolam and its competitive antagonist flumazenil, or vehicle solution (NaCl 0.9%) was injected intravenously to mice 24 h after experimental TBI induced by controlled cortical impact. Mice were evaluated for neurological and motor deficits using a 15-point neuroscore and the rotarod test. Histopathological brain damage and mRNA expression of inflammatory marker genes were analyzed using quantitative polymerase chain reaction three days after insult. Results Histological brain damage was not affected by posttraumatic midazolam administration. Midazolam impaired functional recovery, and this effect could not be counteracted by administering the midazolam antagonist flumazenil. An increase in IL-1β mRNA levels due to postinjury application of midazolam was reversible by flumazenil administration. However, other inflammatory parameters were not affected. Conclusions This study merely reports minor effects of a postinjury midazolam application. Further studies focusing on a time-dependent analysis of posttraumatic benzodiazepine administration are required.https://doi.org/10.1186/s12871-022-01592-xMidazolamFlumazenilBenzodiazepinesγ-aminobutyric acid-A receptorNeurotoxicityTraumatic brain injury
spellingShingle Anne Sebastiani
Simone Bender
Michael K. E. Schäfer
Serge C. Thal
Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury
BMC Anesthesiology
Midazolam
Flumazenil
Benzodiazepines
γ-aminobutyric acid-A receptor
Neurotoxicity
Traumatic brain injury
title Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury
title_full Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury
title_fullStr Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury
title_full_unstemmed Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury
title_short Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury
title_sort posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury
topic Midazolam
Flumazenil
Benzodiazepines
γ-aminobutyric acid-A receptor
Neurotoxicity
Traumatic brain injury
url https://doi.org/10.1186/s12871-022-01592-x
work_keys_str_mv AT annesebastiani posttraumaticmidazolamadministrationdoesnotinfluencebraindamageafterexperimentaltraumaticbraininjury
AT simonebender posttraumaticmidazolamadministrationdoesnotinfluencebraindamageafterexperimentaltraumaticbraininjury
AT michaelkeschafer posttraumaticmidazolamadministrationdoesnotinfluencebraindamageafterexperimentaltraumaticbraininjury
AT sergecthal posttraumaticmidazolamadministrationdoesnotinfluencebraindamageafterexperimentaltraumaticbraininjury